Inhibition of mitogen-activated protein kinase activity of human lymphocytes after oral administration of oltipraz

Molecular Cancer Therapeutics

Volumn 1, Issue 12, 2002, Pages 1125-1128

  Madhukar, Burra V ^a   Dimitrov, Nikolay V ^b   Meyer Leece, Cheryl ^b   Contreras, Margarita L ^b   Crowell, James ^c  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; OLTIPRAZ; PYRAZINE DERIVATIVE;

ADULT; ARTICLE; DRUG EFFECT; ENZYMOLOGY; FEMALE; HUMAN; LUNG TUMOR; LYMPHOCYTE; MALE; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PHOSPHORYLATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ADMINISTRATION, ORAL; ADULT; ANTICARCINOGENIC AGENTS; BLOTTING, WESTERN; ENZYME INHIBITORS; FEMALE; HUMANS; LUNG NEOPLASMS; LYMPHOCYTES; MALE; MAP KINASE SIGNALING SYSTEM; MIDDLE AGED; PHOSPHORYLATION; PYRAZINES; SIGNAL TRANSDUCTION;

EID: 1842870028     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Wattenberg, L. W. Chemoprevention of Cancer. Cancer Res., 45: 1-8, 1985. (Pubitemid 15196921)
2. Dimitrov, N. V., Bennett, J. L., McMillan, J., Perloff, M., Leece, C. M., and Malone W. Clinical pharmacology studies of Oltipraz - a potential chemopreventive agent. Investig. Drugs, 10: 289-298, 1992. (Pubitemid 23008976)
3. Benson, A. B., III. Oltipraz: a laboratory and clinical review. J. Cell Biochem., 17: 278-291, 1993.
4. Kensler, T. W., and Helzlsouer, K. J. Oltipraz. Clinical opportunities for cancer chemoprevention. J. Cell Biochem., 22: 101-107, 1995.
5. Gupta, E., Olopade, O. I., Ratain, M. J., Mick, R., Baker, T. M., Berezin, F. K., Benson, A. B., III, and Dolan, M. E. Pharmacokinetics and pharmacodynamics of Oltipraz as a chemopreventive agent. Clin. Cancer Res., 1: 1133-1138, 1995.
6. Bieder, A., Decouvelaere, B., Gaillard, C., Depaire, H., Heusse, D., Ledoux, D., Lemar, M., LeRoy, J. P., Raynaud, L., Snozzi, C., and Gregoire, J. Comparison of the metabolism of Oltipraz in the mouse, rat, monkey and in man. Arzneim.-Forsch., 33: 1289-1297, 1983.
7. O'Dwyer, P. J., Szarka, C. E., Yao, K. S., Halberr, T. C., Pfeiffer, G. R., Green, F., Gallo, J. M., Brennan, J., Fracht, H., Goosenberg, E. B., Hamilton, T. C., Litwin, S., Balshem, A. M., Engstorm, P. F., and Clapper, M. L. Modulation of gene expression in subjects at risk for colorectal cancer by the chemopreventive agent dithiolethione Oltipraz. J. Clin. Investig., 98: 1210-1217, 1992. (Pubitemid 26299934)
8. Kelloff, G. J., Bodne, C. W., Crowell, J. A., Steel, V., Lubet, R., and Sigman, C. C. Chemopreventive drug development: perspectives and progress. Cancer Epidemiol. Biomark. Prev., 3: 85-98, 1994. (Pubitemid 24172528)
9. Manson, M. M., Ball, H. W., Barrett, M. C., Clark, H. L., Judah, D. J., Williamson, G., and Neal, G. E. Mechanism of action of dietary chemopreventive agents in rat liver: induction of Phase I and II drug metabolizing enzymes and aflatoxin B1 metabolism. Carcinogenesis (Lond.), 18: 1729-1738, 1997. (Pubitemid 28134678)
10. Gudermann, T. Multiple pathways of ERK activation by G protein-coupled receptors. Novartis Found. Symp., 239: 68-79, 2001. (Pubitemid 33599035)
11. Ramirez-De-Molina, A., Rodriguez-Gonzalez, A., and Lacal, J. C. Targeting new anticancer drugs within signaling pathways regulated by Ras GTPase superfamily. Int. J. Oncol., 19: 5-17, 2001.
12. Amundadottir, L. T., and Leder, P. Signal transduction pathways activated and required for mammary carcinogenesis in response to specific oncogenes. Oncogene, 16: 737-746, 1998. (Pubitemid 28076084)
13. Dimitrov, N. V., Leece, C. M., Tompkins, E. R., Seymour, E., Bennink, M., Gardiner, J., Crowell, J., Hawk, E., Nashawaty, M., and Bennet, J. Oltipraz concentrations in plasma, buccal mucosa cells, and lipids: pharmacological studies. Cancer Epidemiol. Biomark. Prev., 10: 201-207, 2001. (Pubitemid 34288530)
14. Böyum, A. Separation of leukocytes from blood and bone marrow. Scand. J. Clin. Lab. Investig., 21 (Suppl. 97): 45-47, 1968.
15. Carson, D. A. Composition and biochemistry of lymphocytes and plasma cells. In: E. Beutler, M. A. Lichtman, B. S. Coller, and T. J. Kipps (eds)., Williams Hematology, 5th Ed, pp. 916-921. New York: The McGraw Hill Companies, 1990.
16. Fischer, L. J., Wagner, M. A., and Madhukar, B. V. Potential involvement of calcium, CaM kinase II, and MAP kinases in PCB-stimulated insulin release from RINm5F cells. Toxicol. Appl. Pharmacol., 159: 194-203, 1999. (Pubitemid 29451127)
17. Towbin, H., Staehelin, T., and Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl. Acad. Sci. USA, 76: 4350-4354, 1979. (Pubitemid 9256559)
18. Robinson, M. J., and Cobb, M. H. Mitogen-activated protein kinase pathways. Curr. Opin. Cell Biol., 9: 180-186, 1997. (Pubitemid 27135985)
19. Cobb, M. H., and Goldsmith, E. J. How MAP kinases are regulated. J. Biol. Chem., 270: 14843-14846, 1995.
20. Kolch, W. Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem. J., 351: 289-305, 2000.
21. Sebolt-Leopald, J. S. Development of anticancer drugs targeting the MAP kinase pathway. Oncogene, 19: 6594-6599, 2000.
22. Carr, B. A., and Franklin, M. R. Induction of drug metabolizing enzymes by 1,7-phenanthroline and Oltipraz in mice is unrelated to Ahresponsiveness. J. Biochem. Mol. Toxicol., 13: 77-82, 1999. (Pubitemid 129705378)